Zum Inhalt springen

Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026

30.09.2026 · 9 Min.

Shownotes

Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.

In this episode
  1. Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page

    Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page # Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme Swapnadip Roy and Vicky Ramancha were indicted on smuggling and conspiracy charges for distributing counterfeit Ozempic, with Roy appearing in a Florida federal court following his extradition from Italy. via CBS…

  2. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz

    Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes # Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes By PR Newswire | September 29, 2026, 6:00 PM In…

  3. Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma

    Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan # Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan By Fraiser Kansteiner Sep 29, 2026 11:20am Finding unique features to pin one’s GLP-1 pitch on has become increasingly important both for developers hoping to catch the next wave of obesity treatments and for Novo’s and Lilly’s…

  4. Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!

    Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! News Release 28-Sep-2026 # Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway New research to be presented at the Annual Meeting of…

  5. Step Back — With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?Background sources

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Alle Folgen von GLP-1 Daily: Ozempic & Wegovy News

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.